PMID- 19766343
OWN - NLM
STAT- MEDLINE
DCOM- 20100108
LR  - 20221207
IS  - 1872-8227 (Electronic)
IS  - 0168-8227 (Linking)
VI  - 86
IP  - 2
DP  - 2009 Nov
TI  - Microvascular diabetic complications are more prevalent in India compared to 
      Mauritius and the UK due to poorer diabetic control.
PG  - e39-40
LID - 10.1016/j.diabres.2009.08.008 [doi]
AB  - Type 2 diabetes mellitus (T2DM) is a growing worldwide problem with WHO estimates 
      suggesting that 300 million people will be affected by 2025. T2DM could result in 
      both microvascular and macrovascular complications but the presentation of these 
      complications could vary globally and be influenced by diabetic control. We 
      investigated the prevalence of these complications by surveying 787 patients of 
      south-Asian origin in diabetic clinics in the UK (n=351), Mauritius (n=173) and 
      India (n=263). We found the prevalence of microvascular complications such as 
      retinopathy (India 16.3%; Mauritius 2.3%; UK 2.6%), nephropathy (India 20.5%; 
      Mauritius 10.5%; UK 2.3%) and neuropathy (India 8.4%; Mauritius 1.2%; UK 5.1%) 
      complications to be significantly higher in India compared to Mauritius and the 
      UK (p<0.05). Interestingly, macrovascular complications such as cardiovascular 
      disease were significantly more prevalent in Mauritius and the UK compared to 
      India (p<0.05). The use of diabetic medication such as Metformin, Sulphonylureas 
      and Insulin was significantly higher in the UK and Mauritius compared to India 
      (p<0.05). The mean HbA1c was significantly higher in India compared to the UK 
      (India 8.68%; UK 8.30%). Our results suggest that microvascular complications are 
      higher in India due to poorer diabetic control. Our findings could be explained 
      by late-onset presentation of diabetic patients in India due to the lack of 
      primary care initiatives to screen and monitor treatment of T2DM. Furthermore, 
      the poor diabetic control in India could reflect a dearth of clinical, 
      evidence-based-knowledge regarding diabetic medication amongst Indian physicians. 
      In view of the global increase in T2DM, this is a major concern for Indian 
      healthcare.
FAU - Potluri, Rahul
AU  - Potluri R
FAU - Purmah, Yanish
AU  - Purmah Y
FAU - Dowlut, Mohammad
AU  - Dowlut M
FAU - Sewpaul, Nilesh
AU  - Sewpaul N
FAU - Lavu, Deepthi
AU  - Lavu D
LA  - eng
PT  - Letter
DEP - 20090918
PL  - Ireland
TA  - Diabetes Res Clin Pract
JT  - Diabetes research and clinical practice
JID - 8508335
RN  - 0 (Glycated Hemoglobin A)
RN  - 0 (Hypoglycemic Agents)
SB  - IM
MH  - Age of Onset
MH  - Aged
MH  - Asian People/ethnology
MH  - Diabetes Mellitus, Type 2/drug therapy/physiopathology/*therapy
MH  - Diabetic Angiopathies/*epidemiology
MH  - Glycated Hemoglobin/metabolism
MH  - Humans
MH  - Hypoglycemic Agents/therapeutic use
MH  - India/epidemiology
MH  - Mauritius/epidemiology
MH  - Microcirculation/*physiology
MH  - Middle Aged
MH  - Prevalence
MH  - United Kingdom
EDAT- 2009/09/22 06:00
MHDA- 2010/01/09 06:00
CRDT- 2009/09/22 06:00
PHST- 2009/05/23 00:00 [received]
PHST- 2009/07/08 00:00 [revised]
PHST- 2009/08/17 00:00 [accepted]
PHST- 2009/09/22 06:00 [entrez]
PHST- 2009/09/22 06:00 [pubmed]
PHST- 2010/01/09 06:00 [medline]
AID - S0168-8227(09)00345-3 [pii]
AID - 10.1016/j.diabres.2009.08.008 [doi]
PST - ppublish
SO  - Diabetes Res Clin Pract. 2009 Nov;86(2):e39-40. doi: 
      10.1016/j.diabres.2009.08.008. Epub 2009 Sep 18.